.Merck trumps profits requirements, raises sales outlook on powerful requirement for leading medicines like Keytruda CNBCMerck & Co. (MRK United States) Defeats Income Projections as Keytruda Sales Surge BloombergMerck Stock: Pharma Giant Posts Tough End Results, However Overview Falls Short Real estate investor's Company DailyMerck Announces Second-Quarter 2024 Financial Outcomes Yahoo FinanceMerck defeats revenue as well as purchases expectations in the middle of Keytruda strength, yet provides blended full-year outlook MarketWatch.